Harm Reduction Therp patents expiration
1. Rivive patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11020343 | HARM REDUCTION THERP | Intranasal pharmaceutical dosage forms comprising naloxone |
May, 2032
(8 years from now) | |
Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 28 July, 2023
Treatment: Use of intranasal naloxone for the treatment of opioid overdose
Dosage: SPRAY, METERED;NASAL
More Information on Dosage
RIVIVE family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic